<DOC>
	<DOCNO>NCT01634503</DOCNO>
	<brief_summary>This study determine maximum tolerable dose ( MTD ) GX 188E define safety profile safety maximum tolerate dose GX-188E administer electroporation Cervical Intraepithelial Neoplasia grade 3 ( CIN 3 ) patient .</brief_summary>
	<brief_title>Safety GX-188E DNA Therapeutic Vaccine Administered Electroporation Cervical Intraepithelial Neoplasia Grade 3</brief_title>
	<detailed_description>This study open-label , dose-escalation , single-center , phase I study evaluate safety GX-188E , DNA-based therapeutic vaccine , administer electroporation ( EP ) patient HPV-16 HPV-18 associate cervical intraepithelial neoplasia grade 3 ( CIN 3 ) . Each subject eligible participate trial give subject number , assign sequentially ascend order , allocate single dose level drug . Three subject allocate dose level start 1mg whereby dose escalate sequential subject ascend numerical order subject ID . Each subject visit site three time administration study give intramuscular injection GX-188E dose 1mg , 2mg 4mg electroporation visit The subject conduct follow-up visit twice , 8 week 24 week third injection GX-188E respectively .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female age 20 50 ( inclusive ) . Those promised get pregnant initiation first followup visit Who diagnose Cervical Intraepithelial Neoplasia 3 histopathologic examination HPV type 16 18 detect Those sign voluntary write informed consent form study participation . Pregnant lactating woman . Administration immunosuppressant immunomodulator within 6 month prior enrollment Concomitant medication corticosteroid agent within 4 week prior vaccination test drug Prior immunotherapy HPV Administration blood product within 3 month prior screen visit Administration vaccine within 4 week prior screen visit ( ex . Hepatitis A vaccine , Hepatitis B vaccine , Influenza vaccine , Td etc . ) Positive serum test result hepatitis C virus , hepatitis B virus surface antigen ( HBsAg ) , HIV Prior participation clinical trial within 30 day prior screen visit Patients predispose inflammatory reaction due use medical device electroporation within 30 day screen visit Past history epilepsy convulsion within 2 year prior screen visit At discretion investigator , skin condition cover deltoid muscle , within 2cm intend site injection , suitable injection due infection , ulcer , edema , tattoo , scar , injury etc . The thickness skin fold cover deltoid muscle , intend injection site , &gt; 40mm Any orthopedic artificial implant around intend site electroporation ( deltoid muscle ) Any history severe adverse drug event severe allergic disease Sinus bradycardia whose rest heart rate &lt; 50beats/min . Preexcitation syndrome WolffParkinsonWhite syndrome Artificial implant metallic implant Abnormal electrocardiography ( ECG ) include arrhythmia Any ineligible condition discretion investigator would ineligible participate study</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>3+3 design</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Cervical Intraepithelial Neoplasia</keyword>
	<keyword>Adult</keyword>
	<keyword>Safety</keyword>
	<keyword>Dose Finding</keyword>
</DOC>